9.4T/20 cm MRI for Cancer Research

用于癌症研究的 9.4T/20 cm MRI

• 批准号: 7389866
• 负责人: JASON Arthur KOUTCHER
• 金额: $ 50万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7389866
• 关键词: Address; Adverse effects; Animals; Biological Models; Blood flow; Brain Neoplasms; Breast Sarcoma; Cancer Detection; Clinic; Clinical; Colon Carcinoma; Data; Development; Drug Delivery Systems; Ensure; Facility Construction Funding Category; Funding Mechanisms; Goals; Human; Hypoxia; Image; Magnetic Resonance Imaging; Methods; Monitor; Noise; Outcome; Oxygen; Peer Review Grants; Performance; Physiological; Policies; Prostate; Range; Research; Research Personnel; Resistance; Signal Transduction; System; Technology; Therapeutic; Toxic effect; Translating; United States National Institutes of Health; anticancer research; base; cancer care; design; drug metabolism; improved; in vivo; instrument; interstitial; oncology; pre-clinical; pressure; research study; response; tumor

DESCRIPTION (provided by applicant): The goal of this application is to obtain support for purchase of a 9.4T 20 cm bore horizontal NMR system for in vivo biomedical applications, focused on cancer research. There are 15 major users with 26 peer reviewed grants who will use the 7T and proposed 9.4T systems. There are a wide range of approaches to addressing different oncologic problems, including cancer detection, predicting tumor response, and developing methods of monitoring tumor and drug metabolism to enhance therapeutic outcomes. The projects are highly translational in that most of these methods can be translated to the clinic, based on the relatively common availability of 3T MRI systems, and the growing (although still limited) availability of human magnets at even higher field strengths. One can summarize the long range goal of these collectively diverse projects as the improvement of cancer care by enhancing responses without correspondingly increased toxicity, either by improving therapies or by development of early markers of response (or resistance) so as to avoid side effects from ineffective treatments. The design and methods of the different projects are diverse but common principles will maximize the data obtained from experiments on the proposed system. These methods include 1) continuing high throughput, relatively straightforward animal imaging research needed by numerous investigators on the existing 4.7T system which has a lower field strength but wide bore and can more readily accommodate multiple animals concurrently, 2) focus more demanding experiments on the 7T and proposed 9.4T systems, 3) where necessary, perform appropriate phantom and preliminary experiments to determine which NIH supported users' experiments will gain relatively more by use of the 9.4T vs the 7T system, 4) the use of statistically valid experimental groups and 5) continue our policy of trying to provide support to the various users in the design of experiments, construction of appropriate hardware, and if necessary, assisting in the performance of the experiments to ensure that they are performed in an optimized manner, with best signal to noise possible. The applications that will be supported on the proposed 9.4T instrument address a wide range of oncology problems, as reflected by the different funding mechanisms from which they arise. These include a focus on a wide spectrum of tumors (brain, prostate, breast, sarcomas, colon cancers), addressing varying relevant physiological problems in oncology (hypoxia (lack of oxygen), elevated tumor interstitial pressure leading to poor blood flow and drug delivery, the need for better tumor model systems, improvements in imaging etc). The approaches to addressing these problems are quite varied but have in common the feasibility to readily translate any of these findings from the preclinical to the clinical realm, based on existing technology.

描述（由申请人提供）：本申请的目标是获得购买 9.4T 20 cm 孔径水平 NMR 系统的支持，用于体内生物医学应用，重点是癌症研究。有 15 个主要用户（拥有 26 个同行评审资助）将使用 7T 和拟议的 9.4T 系统。有多种方法可以解决不同的肿瘤问题，包括癌症检测、预测肿瘤反应以及开发监测肿瘤和药物代谢的方法以增强治疗效果。这些项目具有高度转化性，因为基于 3T MRI 系统相对普遍的可用性，以及在更高场强下人体磁体的可用性不断增长（尽管仍然有限），大多数这些方法都可以转化为临床。人们可以将这些集体不同项目的长期目标总结为通过增强反应而不相应增加毒性来改善癌症护理，或者通过改进疗法或通过开发反应（或耐药性）的早期标志物以避免无效的副作用治疗。不同项目的设计和方法各不相同，但共同的原则将最大限度地利用所提出系统的实验获得的数据。这些方法包括 1) 众多研究人员需要在现有 4.7T 系统上进行持续的高通量、相对简单的动物成像研究，该系统具有较低的场强但孔径较宽，可以更容易地同时容纳多个动物，2) 将更苛刻的实验集中在7T 和建议的 9.4T 系统，3) 必要时，进行适当的模型和初步实验，以确定哪些 NIH 支持的用户的实验将通过使用 9.4T 与 7T 系统获得相对更多，4)使用统计上有效的实验组，5) 继续我们的政策，努力在实验设计、构建适当的硬件方面为各种用户提供支持，并在必要时协助实验的进行，以确保实验的进行一种优化的方式，尽可能实现最佳的信噪比。拟议的 9.4T 仪器将支持的应用程序解决了广泛的肿瘤学问题，正如它们产生的不同资助机制所反映的那样。其中包括关注广泛的肿瘤（脑癌、前列腺癌、乳腺癌、肉瘤、结肠癌），解决肿瘤学中各种相关的生理问题（缺氧（缺氧）、肿瘤间质压力升高导致血流和药物输送不良） ，需要更好的肿瘤模型系统，成像技术的改进等）。解决这些问题的方法多种多样，但共同点是可以根据现有技术轻松地将这些发现从临床前领域转化为临床领域。